Zacks Investment Research upgraded shares of KALOBIOS PHARMA (KBIO) from NEUTRAL to OUTPERFORM on July 02, 2014, with a target price of $2.50.
KaloBios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company develops monoclonal antibody therapeutics for the treatment of respiratory diseases and cancer. KaloBios Pharmaceuticals, Inc. is based in South San Francisco, California.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on KALOBIOS PHARMA (KBIO),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment